Suppression of mammalian K+ channel family by ebastine.
暂无分享,去创建一个
M. Morad | I. Ducić | Y. Shuba | I Ducic | M Morad | C. Ko | J. Fan | C M Ko | J Fan | Y M Shuba | Ivan Ducic | Martin Morad | Chang Mann Ko | Jing Fan | Yaroslav Shuba
[1] G. Romey,et al. Molecular biology of voltage‐gated K+ channels in heart , 1994, Fundamental & clinical pharmacology.
[2] J. Lynch,et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.
[3] C. L. Ferguson,et al. Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.
[4] R. Woosley,et al. Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.
[5] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[6] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[7] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[8] Gary Yellen,et al. The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.
[9] T M Craft,et al. Torsade de pointes after astemizole overdose. , 1986, British medical journal.
[10] R. Harvey,et al. Chloride conductance pathways in heart. , 1991, The American journal of physiology.
[11] Y Chen,et al. Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.
[12] M. Sanguinetti,et al. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.
[13] R Lazzara,et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.
[14] A. Stanners,et al. Torsades de pointes complicating treatment with terfenadine. , 1991, BMJ.
[15] R. Egan,et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. , 1996, Arzneimittel-Forschung.
[16] A. Fabiato,et al. Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. , 1988, Methods in enzymology.
[17] C. Berul,et al. Regulation of potassium channels by nonsedating antihistamines. , 1995, Circulation.
[18] D. Roden,et al. Molecular cloning and characterization of two voltage‐gated K+ channel cDNAs from human ventricle , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[20] W. Crumb,et al. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. , 1995, Molecular pharmacology.
[21] A. Brown,et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.
[22] R. Egan,et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. , 1996, Arzneimittel-Forschung.